Published in Blood Weekly, October 10th, 2002
The incidence of biopsy proven acute rejection in patients undergoing kidney transplantation proved to be low in both therapeutic combinations. Additionally, patients assigned to the Prograf-CellCept combination experienced better renal function and exhibited less cardiovascular risk factors including hyperlipidemia and diastolic hypertension.
"Studies such as this that show Prograf can be combined safely with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.